ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Keyword Index

Click a keyword to view all the abstracts on this site tagged with that keyword.

  • prevention and ulcers
  • prevention and uric acid
  • prevention and vaccines
  • prevention and vasculitis
  • primary care
  • primary care and healthcare system
  • Primary care and psoriatic arthritis
  • primary care and qualitative
  • primary care and quality improvement
  • primary care and rheumatic disease
  • primary care and rheumatoid arthritis
  • primary care and rheumatoid arthritis (RA)
  • primary care and spondylarthropathy
  • primary care and temporal arteritis
  • primary care and uric acid
  • primary immunodeficiency and vasculitis
  • primary sjogren's syndrome
  • prior authorization
  • Prior authorization and quality improvement
  • prior authorization and rheumatic disease
  • pristane induced C57BL/6 mouse model
  • Private Practice
  • PRKG1
  • PRO
  • PRO and Disease Activity
  • PRO and patient outcomes
  • PRO and rheumatic disease
  • PRO and rheumatoid arthritis (RA)
  • PRO and SLE
  • PRO and systemic lupus erythematosus (SLE)
  • Probabilistic Estimation
  • Probability Score
  • Procalcitonin
  • productive
  • productive and qualitative
  • productive and work
  • professionalism and trainee
  • profile and Biologics
  • Prognosis
  • prognostic biomarkers and immunoassays
  • prognostic factors
  • prognostic factors and activity score
  • prognostic factors and biomarkers
  • prognostic factors and heart disease
  • prognostic factors and outcomes
  • prognostic factors and proteinuria
  • prognostic factors and psoriatic arthritis
  • prognostic factors and pulmonary fibrosis
  • prognostic factors and quality of life
  • prognostic factors and radiography
  • prognostic factors and remission
  • prognostic factors and rheumatic disease
  • prognostic factors and rheumatoid arthritis
  • Prognostic factors and rheumatoid arthritis (RA)
  • prognostic factors and salivary gland
  • prognostic factors and sarcoidosis
  • prognostic factors and spondylarthritis
  • prognostic factors and synovitis
  • prognostic factors and synovium
  • prognostic factors and systemic lupus erythematosus (SLE)
  • prognostic factors and systemic sclerosis
  • prognostic factors and tendonitis/bursitis
  • prognostic factors and therapy
  • prognostic factors and thrombosis
  • prognostic factors and tobacco use
  • prognostic factors and treatment
  • prognostic factors and ultrasonography
  • prognostic factors and ultrasound
  • prognostic factors and uric acid
  • prognostic factors and uveitis
  • prognostic factors and vasculitis
  • progression
  • prolactin
  • prolactin and rheumatoid arthritis (RA)
  • prolactin and systemic lupus erythematosus (SLE)
  • proliferative lupus nephritis
  • PROMIS
  • PROMIS and alternative medicine
  • PROMIS and Disease Activity
  • PROMIS and outcome measures
  • PROMIS and patient outcomes
  • PROMIS and physical function
  • PROMIS and rheumatoid arthritis (RA)
  • PROMIS and Rheumatologic Conditions
  • PROMIS and rheumatology
  • promis-29
  • PROs
  • prospective
  • prostacyclin
  • prostaglandins
  • prostaglandins and psoriasis
  • prostaglandins and resolution of disease
  • prostaglandins and rheumatoid arthritis
  • prostaglandins and rheumatoid arthritis (RA)
  • Prostaglandins and scleroderma
  • prostaglandins and systemic sclerosis
  • prostaglandins and toll-like receptors
  • prosthesis
  • prosthesis and pseudogout
  • prosthesis and rheumatoid arthritis (RA)
  • Prosthetic Joint
  • prosthetic joint infection
  • Protein Kinase
  • proteinuria
  • proteinuria and renal disease
  • proteinuria and systemic lupus erythematosus (SLE)
  • proteoglycans
  • proteoglycans and rheumatoid arthritis (RA)
  • proteoglycans and transforming growth factor
  • proteoglycans and treatment
  • Proteome
  • proteomics
  • proteomics and fibroblasts
  • proteomics and machine learning
  • Proteomics and psoriatic arthritis
  • proteomics and radiography
  • proteomics and rheumatic disease
  • proteomics and rheumatoid arthritis
  • proteomics and rheumatoid arthritis (RA)
  • proteomics and salivary gland
  • proteomics and salivary hypofunction
  • proteomics and scleroderma
  • proteomics and systemic lupus erythematosus (SLE)
  • proteomics and systemic sclerosis
  • proteomics and tumor necrosis factor (TNF)
  • proteomics and uveitis
  • proteomics and vasculitis
  • Proton pump inhibitor
  • PRP
  • PsA
  • psa and bone density
  • pseudogout
  • pseudogout and chondrocalcinosis
  • pseudotime and resource
  • psoriasis
  • psoriasis and anti-TNF therapy
  • psoriasis and comorbidity
  • psoriasis and Disease Activity
  • psoriasis and DMARDs
  • psoriasis and epidemiology
  • psoriasis and heart disease
  • psoriasis and inflammation
  • psoriasis and patient questionnaires
  • psoriasis and psoriatic arthritis
  • psoriasis and questionnaires
  • psoriasis and rheumatic disease
  • psoriasis and rheumatoid arthritis
  • psoriasis and rheumatoid arthritis (RA)
  • Psoriasis and safety
  • psoriasis and signal transduction
  • psoriasis and skin
  • psoriasis and spondylarthritis
  • psoriasis and tissue growth factor (TGF)
  • psoriasis and tumor necrosis factor (TNF)
  • psoriasis and tyrosine kinase inhibition
  • psoriasis and ultrasound
  • Psoriatic arthritis
  • Psoriatic arthritis (PsA)
  • psoriatic arthritis and anemia
  • psoriatic arthritis and ankylosing spondylitis (AS)
  • psoriatic arthritis and Biologics
  • psoriatic arthritis and body mass
  • psoriatic arthritis and clinical trials
  • psoriatic arthritis and complementary and alternative medicine
  • psoriatic arthritis and Disease Activity
  • psoriatic arthritis and Enthesitis
  • psoriatic arthritis and metabolic syndrome
  • psoriatic arthritis and multicenter study
  • psoriatic arthritis and Oligoarthritis
  • psoriatic arthritis and pain
  • psoriatic arthritis and patient outcomes
  • psoriatic arthritis and patient-reported outcome measures
  • psoriatic arthritis and predictifs factors
  • psoriatic arthritis and psoriasis
  • Psoriatic arthritis and qualitative
  • psoriatic arthritis and quality of life
  • psoriatic arthritis and questionnaires
  • psoriatic arthritis and radiography
  • psoriatic arthritis and radiology
  • psoriatic arthritis and randomized trials
  • psoriatic arthritis and registries
  • psoriatic arthritis and registry
  • psoriatic arthritis and relapse
  • psoriatic arthritis and remission
  • psoriatic arthritis and research methods
  • psoriatic arthritis and rheumatic disease
  • Psoriatic arthritis and rheumatoid arthritis
  • psoriatic arthritis and rheumatoid arthritis (RA)
  • psoriatic arthritis and rheumatologic practice
  • psoriatic arthritis and risk
  • psoriatic arthritis and risk assessment
  • Psoriatic arthritis and safety
  • psoriatic arthritis and SAPHO syndrome
  • psoriatic arthritis and serologic tests
  • Psoriatic arthritis and severity
  • psoriatic arthritis and shared dicision making
  • psoriatic arthritis and signal transduction
  • psoriatic arthritis and skin
  • Psoriatic arthritis and sleep
  • psoriatic arthritis and sleep disorders
  • First |
  • « Previous Page
  • 47
  • 48
  • 49
  • 50
  • 51
  • [52]
  • 53
  • 54
  • 55
  • 56
  • 57
  • Next Page »
  • | Last
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology